{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:00:43Z","timestamp":1795035643605,"version":"4.10.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020559","name":"Fondazione \u201cLa Nuova Speranza\u201d Onlus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020559","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Children with multi-drug resistant idiopathic nephrotic syndrome (MDR-INS) usually progress to end-stage kidney disease with a consistent risk of disease recurrence after transplantation. New therapeutic options are needed for these patients. Mesenchymal stromal cells (MSCs) are multipotential non-hematopoietic cells with several immunomodulatory properties and growing clinical applications. Cord blood-derived MSC have peculiar anti-inflammatory and immunosuppressive properties. We aimed at assessing safety and efficacy of cord-blood-derived MSCs (CB-MSCs) in children with MDR-INS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants<\/jats:title>\n                    <jats:p>\n                      Prospective, open-label, single arm phase I\u2013II pilot study. Pediatric patients with MDR-INS, resistant to at least two lines of therapy, were enrolled. Allogenic CB-MSCs were administered intravenously on days 0, 14, and 21 at a dose of 1.5\u2009\u00d7\u200910\n                      <jats:sup>6<\/jats:sup>\n                      cells\/kg. Patients were followed for at least 12\u00a0months. The primary outcomes were safety and toxicity. The secondary outcome was remission at 12\u00a0months evaluated by urinary protein\/urinary creatinine ratio (uPr\/uCr). Circulating regulatory T cells (Tregs) were monitored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven pediatric patients with MDR-INS (10 females, median age 13\u00a0years) resistant to a median of 3 previous lines of therapy were enrolled. All patients completed the CB-MSC infusion schedule. No patient experienced any infusion-related adverse event or toxicity. Nine patients were assessable for efficacy. At the 12\u00a0months follow-up after the treatment, the median uPr\/uCr did not change significantly from baseline (8.13 vs. 9.07;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.98), while 3 patients were in partial or complete remission. A lower baseline uPr\/uCr was a predictor of remission (2.55 vs. 8.74;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0238). Tregs count was not associated with CB-MSCs therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CB-MSCs are safe and may have a role in the immunosuppressive therapy of pediatric patients with MDR-INS. This preliminary experience paves the way toward further phase II studies addressing MSC efficacy in immune-mediated kidney diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-022-03112-7","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T04:03:58Z","timestamp":1660881838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-4128","authenticated-orcid":false,"given":"William","family":"Morello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Budelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Ari","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Montelatici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Lavazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Ghio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Edefonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Molino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Benetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Gianoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Mehmeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Catenacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rotella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tamburello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-4475","authenticated-orcid":false,"given":"Giovanni","family":"Montini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"issue":"10141","key":"3112_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(18)30536-1.","journal-title":"Lancet"},{"key":"3112_CR2","unstructured":"Niaudet P. Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children - UpToDate. In: Post TW, ed. UpToDate; 2019."},{"issue":"1","key":"3112_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13052-017-0356-x","volume":"43","author":"A Pasini","year":"2017","unstructured":"Pasini A, Benetti E, Conti G, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I\u2014diagnosis and treatment of the first episode and the first relapse. Ital J Pediatr. 2017;43(1):41. https:\/\/doi.org\/10.1186\/s13052-017-0356-x.","journal-title":"Ital J Pediatr"},{"issue":"4","key":"3112_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40620-019-00660-9","volume":"33","author":"W Morello","year":"2020","unstructured":"Morello W, Puvinathan S, Puccio G, et al. Post-transplant recurrence of steroid resistant nephrotic syndrome in children: the Italian experience. J Nephrol. 2020;33(4):849\u201357. https:\/\/doi.org\/10.1007\/s40620-019-00660-9.","journal-title":"J Nephrol"},{"issue":"10","key":"3112_CR5","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1182\/blood-2007-02-069716","volume":"110","author":"AJ Nauta","year":"2007","unstructured":"Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499\u2013506. https:\/\/doi.org\/10.1182\/blood-2007-02-069716.","journal-title":"Blood"},{"issue":"4","key":"3112_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137. https:\/\/doi.org\/10.1080\/14653240600855905.","journal-title":"Cytotherapy"},{"issue":"5","key":"3112_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14653240500319234","volume":"7","author":"EM Horwitz","year":"2005","unstructured":"Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393\u20135. https:\/\/doi.org\/10.1080\/14653240500319234.","journal-title":"Cytotherapy"},{"issue":"1","key":"3112_CR8","doi-asserted-by":"publisher","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, Chiu SM, Motan DAL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062\u2013e2062. https:\/\/doi.org\/10.1038\/cddis.2015.327.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3112_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/SCD.2014.0160","volume":"24","author":"M Barilani","year":"2015","unstructured":"Barilani M, Lavazza C, Vigan\u00f2 M, et al. Dissection of the cord blood stromal component reveals predictive parameters for culture outcome. Stem Cells Dev. 2015;24(1):104. https:\/\/doi.org\/10.1089\/SCD.2014.0160.","journal-title":"Stem Cells Dev"},{"issue":"1","key":"3112_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-86147-9","volume":"11","author":"M Brennan","year":"2021","unstructured":"Brennan M, Barilani M, Rusconi F, et al. Chondrogenic and BMP-4 primings confer osteogenesis potential to human cord blood mesenchymal stromal cells delivered with biphasic calcium phosphate ceramics. Sci Rep. 2021;11(1):1\u201315. https:\/\/doi.org\/10.1038\/s41598-021-86147-9.","journal-title":"Sci Rep"},{"issue":"2","key":"3112_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1681\/asn.2017070781","volume":"29","author":"N Perico","year":"2017","unstructured":"Perico N, Casiraghi F, Remuzzi G. Clinical translation of mesenchymal stromal cell therapies in nephrology. J Am Soc Nephrol. 2017;29(2):362\u201375. https:\/\/doi.org\/10.1681\/asn.2017070781.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"3112_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3324\/haematol.11240","volume":"92","author":"C Prevosto","year":"2007","unstructured":"Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92(7):881\u20138. https:\/\/doi.org\/10.3324\/haematol.11240.","journal-title":"Haematologica"},{"issue":"7","key":"3112_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41418-017-0006-2","volume":"25","author":"G Wang","year":"2018","unstructured":"Wang G, Cao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ. 2018;25(7):1209\u201323. https:\/\/doi.org\/10.1038\/s41418-017-0006-2.","journal-title":"Cell Death Differ"},{"issue":"12","key":"3112_CR14","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/J.EXPHEM.2009.09.004","volume":"37","author":"J Kim","year":"2009","unstructured":"Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. 2009;37(12):1445\u201353. https:\/\/doi.org\/10.1016\/J.EXPHEM.2009.09.004.","journal-title":"Exp Hematol"},{"issue":"1","key":"3112_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01.TP.0000244572.24780.54","volume":"83","author":"R Ramasamy","year":"2007","unstructured":"Ramasamy R, Fazekasova H, Lam EWF, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007;83(1):71\u20136. https:\/\/doi.org\/10.1097\/01.TP.0000244572.24780.54.","journal-title":"Transplantation"},{"issue":"10","key":"3112_CR16","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1182\/BLOOD.V99.10.3838","volume":"99","author":"NM Di","year":"2002","unstructured":"Di NM, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838\u201343. https:\/\/doi.org\/10.1182\/BLOOD.V99.10.3838.","journal-title":"Blood"},{"issue":"1","key":"3112_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13287-020-01612-Y\/FIGURES\/7","volume":"11","author":"QH Chen","year":"2020","unstructured":"Chen QH, Wu F, Liu L, et al. Mesenchymal stem cells regulate the Th17\/Treg cell balance partly through hepatocyte growth factor in vitro. Stem Cell Res Ther. 2020;11(1):1\u201311. https:\/\/doi.org\/10.1186\/S13287-020-01612-Y\/FIGURES\/7.","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"3112_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1097\/TP.0B013E3181FED001","volume":"90","author":"W Ge","year":"2010","unstructured":"Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90(12):1312\u201320. https:\/\/doi.org\/10.1097\/TP.0B013E3181FED001.","journal-title":"Transplantation"},{"key":"3112_CR19","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3389\/FIMMU.2020.01156\/BIBTEX","volume":"11","author":"M Magatti","year":"2020","unstructured":"Magatti M, Masserdotti A, Bonassi Signoroni P, et al. B Lymphocytes as targets of the immunomodulatory properties of human amniotic mesenchymal stromal cells. Front Immunol. 2020;11:1156. https:\/\/doi.org\/10.3389\/FIMMU.2020.01156\/BIBTEX.","journal-title":"Front Immunol"},{"key":"3112_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1287-9","author":"L Zhao","year":"2019","unstructured":"Zhao L, Chen S, Yang P, Cao H, Li L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: Prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019. https:\/\/doi.org\/10.1186\/s13287-019-1287-9.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"3112_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00277-018-3384-8","volume":"97","author":"L Wang","year":"2018","unstructured":"Wang L, Zhu CY, Ma DX, et al. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Ann Hematol. 2018;97(10):1941\u201350. https:\/\/doi.org\/10.1007\/s00277-018-3384-8.","journal-title":"Ann Hematol"},{"issue":"3","key":"3112_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629\u201337. https:\/\/doi.org\/10.1681\/ASN.2008030287.","journal-title":"J Am Soc Nephrol"},{"key":"3112_CR23","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.2147\/DDDT.S80403","volume":"9","author":"T Montemurro","year":"2015","unstructured":"Montemurro T, Vigan\u00f2 M, Budelli S, et al. How we make cell therapy in Italy. Drug Des Devel Ther. 2015;9:4825\u201334. https:\/\/doi.org\/10.2147\/DDDT.S80403.","journal-title":"Drug Des Devel Ther"},{"key":"3112_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3038565","author":"M Vigan\u00f2","year":"2018","unstructured":"Vigan\u00f2 M, Budelli S, Lavazza C, et al. Tips and tricks for validation of quality control analytical methods in good manufacturing practice mesenchymal stromal cell production. Stem Cells Int. 2018. https:\/\/doi.org\/10.1155\/2018\/3038565.","journal-title":"Stem Cells Int."},{"issue":"7","key":"3112_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2217\/RME-2017-0051\/ASSET\/IMAGES\/LARGE\/FIGURE1.JPEG","volume":"12","author":"M Vigan\u00f2","year":"2017","unstructured":"Vigan\u00f2 M, Giordano R, Lazzari L. Challenges of running a GMP facility for regenerative medicine in a public hospital. Regen Med. 2017;12(7):803\u201313. https:\/\/doi.org\/10.2217\/RME-2017-0051\/ASSET\/IMAGES\/LARGE\/FIGURE1.JPEG.","journal-title":"Regen Med"},{"issue":"11","key":"3112_CR26","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/J.BBMT.2018.07.015","volume":"24","author":"C Trento","year":"2018","unstructured":"Trento C, Bernardo ME, Nagler A, et al. Manufacturing mesenchymal stromal cells for the treatment of graft-versus-host disease: a survey among centers affiliated with the European society for blood and marrow transplantation. Biol Blood Marrow Transpl. 2018;24(11):2365\u201370. https:\/\/doi.org\/10.1016\/J.BBMT.2018.07.015.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3112_CR27","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.; 2017."},{"key":"3112_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/434010","author":"G Kleiner","year":"2013","unstructured":"Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. Mediators Inflamm. 2013. https:\/\/doi.org\/10.1155\/2013\/434010.","journal-title":"Mediators Inflamm"},{"issue":"11","key":"3112_CR29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/J.JCLINEPI.2015.04.014","volume":"68","author":"W Viechtbauer","year":"2015","unstructured":"Viechtbauer W, Smits L, Kotz D, et al. A simple formula for the calculation of sample size in pilot studies. J Clin Epidemiol. 2015;68(11):1375\u20139. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2015.04.014.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"3112_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"DC Cattran","year":"2012","unstructured":"Cattran DC, Feehally J, Cook HT, et al. Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139\u2013274. https:\/\/doi.org\/10.1038\/kisup.2012.9.","journal-title":"Kidney Int Suppl"},{"key":"3112_CR31","unstructured":"Niaudet P, Gillion Boyer O. Steroid-resistant idiopathic nephrotic syndrome in children: Management. In: Post TW, ed. Waltham, MA: UpToDate; 2018."},{"issue":"3","key":"3112_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00467-007-0640-x","volume":"23","author":"M Nakayama","year":"2008","unstructured":"Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol. 2008;23(3):481\u20135. https:\/\/doi.org\/10.1007\/s00467-007-0640-x.","journal-title":"Pediatr Nephrol"},{"issue":"26","key":"3112_CR33","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1056\/NEJMc063706","volume":"356","author":"A Bagga","year":"2007","unstructured":"Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356(26):2751\u20132. https:\/\/doi.org\/10.1056\/NEJMc063706.","journal-title":"N Engl J Med"},{"issue":"6","key":"3112_CR34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012;23(6):1117\u201324. https:\/\/doi.org\/10.1681\/ASN.2011080775.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3112_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol. 2013;28(2):257\u201364. https:\/\/doi.org\/10.1007\/s00467-012-2319-1.","journal-title":"Pediatr Nephrol"},{"issue":"13","key":"3112_CR36","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMc1308488","volume":"370","author":"B Basu","year":"2014","unstructured":"Basu B. Ofatumumab for Rituximab-Resistant Nephrotic Syndrome. N Engl J Med. 2014;370(13):1268\u201370. https:\/\/doi.org\/10.1056\/NEJMc1308488.","journal-title":"N Engl J Med"},{"issue":"5","key":"3112_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00467-017-3621-8","volume":"32","author":"C-S Wang","year":"2017","unstructured":"Wang C-S, Liverman RS, Garro R, et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol. 2017;32(5):835\u201341. https:\/\/doi.org\/10.1007\/s00467-017-3621-8.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"3112_CR38","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/trf.12421","volume":"54","author":"RR Sharma","year":"2014","unstructured":"Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion. 2014;54(5):1418\u201337. https:\/\/doi.org\/10.1111\/trf.12421.","journal-title":"Transfusion"},{"issue":"1","key":"3112_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pathol-011110-130230","volume":"6","author":"NG Singer","year":"2011","unstructured":"Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol Mech Dis. 2011;6(1):457\u201378. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130230.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"4","key":"3112_CR40","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","volume":"105","author":"S Aggarwal","year":"2005","unstructured":"Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815\u201322. https:\/\/doi.org\/10.1182\/blood-2004-04-1559.","journal-title":"Blood"},{"issue":"8","key":"3112_CR41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","volume":"14","author":"J Hou","year":"2018","unstructured":"Hou J, Wang Y, Liu K, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493\u2013507. https:\/\/doi.org\/10.1038\/s41581-018-0023-5.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3112_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1681\/asn.2007111244","volume":"20","author":"L Le Berre","year":"2008","unstructured":"Le Berre L, Bruneau S, Naulet J, et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol. 2008;20(1):57\u201367. https:\/\/doi.org\/10.1681\/asn.2007111244.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3112_CR43","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","volume":"24","author":"XS Shao","year":"2009","unstructured":"Shao XS, Yang XQ, Zhao XD, et al. The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome. Pediatr Nephrol. 2009;24(9):1683\u201390. https:\/\/doi.org\/10.1007\/s00467-009-1194-x.","journal-title":"Pediatr Nephrol"},{"key":"3112_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/J.CELLIMM.2017.11.010","volume":"326","author":"K Qi","year":"2018","unstructured":"Qi K, Li N, Zhang Z, Melino G. Tissue regeneration: the crosstalk between mesenchymal stem cells and immune response. Cell Immunol. 2018;326:86\u201393. https:\/\/doi.org\/10.1016\/J.CELLIMM.2017.11.010.","journal-title":"Cell Immunol"},{"key":"3112_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7828","author":"A Galleu","year":"2017","unstructured":"Galleu A, Riffo-Vasquez Y, Trento C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aam7828.","journal-title":"Sci Transl Med."}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-03112-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-022-03112-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-03112-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T04:09:42Z","timestamp":1660882182000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-022-03112-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3112"],"URL":"https:\/\/doi.org\/10.1186\/s13287-022-03112-7","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"23 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (Comitato Etico Milano Area 2) and by the national competent authorities for clinical trial authorization (Istituto Superiore di Sanit\u00e0 and Agenzia Italiana del Farmaco [AIFA]). The trial was registered befor the enrollment of the first patient (EudraCT number 2011-001387-21). An informed consent was obtained from the legal guardians of all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest relevant to this article to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"420"}}